<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Gonadotrophins for ovulation induction in women with polycystic ovary syndrome - Weiss, NS - 2019 | Cochrane Library</title> <meta content="Gonadotrophins for ovulation induction in women with polycystic ovary syndrome - Weiss, NS - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010290.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Gonadotrophins for ovulation induction in women with polycystic ovary syndrome - Weiss, NS - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010290.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010290.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Gonadotrophins for ovulation induction in women with polycystic ovary syndrome" name="citation_title"/> <meta content="Nienke S Weiss" name="citation_author"/> <meta content="Amsterdam UMC, Free Medical University" name="citation_author_institution"/> <meta content="Elena Kostova" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Marleen Nahuis" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="Ben Willem J Mol" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Fulco van der Veen" name="citation_author"/> <meta content="Amsterdan UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Madelon van Wely" name="citation_author"/> <meta content="Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="m.vanwely@amc.uva.nl" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010290.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010290.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010290.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010290.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abortion, Spontaneous [epidemiology]; Birth Rate; Clomiphene [therapeutic use]; Drug Resistance; Fertility Agents, Female [*therapeutic use]; Follicle Stimulating Hormone [therapeutic use]; Gonadotropins [*therapeutic use]; Live Birth [epidemiology]; Menotropins [therapeutic use]; Ovarian Hyperstimulation Syndrome [chemically induced, epidemiology]; Ovulation Induction [*methods]; Polycystic Ovary Syndrome [*drug therapy]; Pregnancy, Multiple [statistics &amp; numerical data]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010290.pub3&amp;doi=10.1002/14651858.CD010290.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010290\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010290\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","th","ms","ja","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010290.pub3",title:"Gonadotrophins for ovulation induction in women with polycystic ovary syndrome",firstPublishedDate:"Jan 16, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010290.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010290.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010290.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010290.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010290.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010290.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010290.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010290.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010290.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010290.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8720 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010290.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/appendices#CD010290-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/table_n/CD010290StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/table_n/CD010290StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Gonadotrophins for ovulation induction in women with polycystic ovary syndrome</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#CD010290-cr-0002">Nienke S Weiss</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#CD010290-cr-0003">Elena Kostova</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#CD010290-cr-0004">Marleen Nahuis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#CD010290-cr-0005">Ben Willem J Mol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#CD010290-cr-0006">Fulco van der Veen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information#CD010290-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Madelon van Wely</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information/en#CD010290-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010290.pub3">https://doi.org/10.1002/14651858.CD010290.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010290-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010290-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010290-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010290-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010290-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD010290-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010290-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010290-abs-0001" lang="en"> <section id="CD010290-sec-0001"> <h3 class="title" id="CD010290-sec-0001">Background</h3> <p>Ovulation induction with follicle stimulating hormone (FSH) is a second‐line treatment in women with polycystic ovary syndrome (PCOS) who do not ovulate or conceive on clomiphene citrate. </p> </section> <section id="CD010290-sec-0002"> <h3 class="title" id="CD010290-sec-0002">Objectives</h3> <p>To compare the effectiveness and safety of gonadotrophins as a second‐line treatment for ovulation induction in women with clomiphene citrate‐resistant polycystic ovary syndrome (PCOS), and women who do not ovulate or conceive after clomiphene citrate. </p> </section> <section id="CD010290-sec-0003"> <h3 class="title" id="CD010290-sec-0003">Search methods</h3> <p>In January 2018, we searched the Cochrane Gynaecology and Fertility Group Specialised Register of Controlled Trials, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, the World Health Organisation clinical trials register, Clinicaltrials.gov, LILACs, and PubMed databases, and Google Scholar. We checked references of in all obtained studies. We had no language restrictions. </p> </section> <section id="CD010290-sec-0004"> <h3 class="title" id="CD010290-sec-0004">Selection criteria</h3> <p>All randomised controlled trials reporting data on clinical outcomes in women with PCOS who did not ovulate or conceive on clomiphene citrate, and undergoing ovulation induction with urinary‐derived gonadotrophins, including urofollitropin (uFSH) in purified FSH (FSH‐P) or highly purified FSH (FSH‐HP) form, human menopausal gonadotropin (HMG) and highly purified human menopausal gonadotrophin (HP‐HMG), or recombinant FSH (rFSH), or continuing clomiphene citrate. We included trials reporting on ovulation induction followed by intercourse or intrauterine insemination. We excluded studies that described co‐treatment with clomiphene citrate, metformin, luteinizing hormone, or letrozole. </p> </section> <section id="CD010290-sec-0005"> <h3 class="title" id="CD010290-sec-0005">Data collection and analysis</h3> <p>Three review authors (NW, EK, and MvW) independently selected studies for inclusion, assessed risk of bias, and extracted study data. Primary outcomes were live birth rate per woman and multiple pregnancy per woman. Secondary outcomes were clinical pregnancy, miscarriage, incidence of ovarian hyperstimulation syndrome (OHSS) per woman, total gonadotrophin dose, and total duration of stimulation per woman. We combined data using a fixed‐effect model to calculate the risk ratio (RR). We summarised the overall quality of evidence for the main outcomes using GRADE criteria. </p> </section> <section id="CD010290-sec-0006"> <h3 class="title" id="CD010290-sec-0006">Main results</h3> <p>The review included 15 trials with 2387 women. Ten trials compared rFSH with urinary‐derived gonadotrophins (three compared rFSH with human menopausal gonadotrophin, and seven compared rFSH with FSH‐HP), four trials compared FSH‐P with HMG. We found no trials that compared FSH‐HP with FSH‐P. One trial compared FSH with continued clomiphene citrate. </p> <p><b>Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins</b> </p> <p>There may be little or no difference in the birth rate between rFSH and urinary‐derived gonadotrophins (RR 1.21, 95% confidence interval (CI) 0.83 to 1.78; five trials, N = 505; I² = 9%; low‐quality evidence). This suggests that for the observed average live birth per woman who used urinary‐derived FSH of 16%, the chance of live birth with rFSH is between 13% and 28%. There may also be little or no difference between groups in incidence of multiple pregnancy (RR 0.86, 95% CI 0.46 to 1.61; eight trials, N = 1368; I² = 0%; low‐quality evidence), clinical pregnancy rate (RR 1.05, 95% CI 0.88 to 1.27; eight trials, N = 1330; I² = 0; low‐quality evidence), or miscarriage rate (RR 1.20, 95% CI 0.71 to 2.04; seven trials, N = 970; I² = 0; low‐quality evidence). We are uncertain whether rFSH reduces the incidence of OHSS (RR 1.48, 95% CI 0.82 to 2.65, ten trials, n=1565, I² = 0%, very low‐quality evidence). </p> <p><b>Human menopausal gonadotrophin (HMG) or HP‐HMG versus uFSH</b> </p> <p>When compared to uFSH, we are uncertain whether HMG or HP‐HMG improves live birth rate (RR 1.28, 95% CI 0.65 to 2.52; three trials, N = 138; I² = 0%; very low quality evidence), or reduces multiple pregnancy rate (RR 2.13, 95% CI 0.51 to 8.91; four trials, N = 161; I² = 0%; very low quality evidence). We are also uncertain whether HMG or HP‐HMG improves clinical pregnancy rate (RR 1.31, 95% CI 0.66 to 2.59; three trials, N = 102; I² = 0; very low quality evidence), reduces miscarriage rate (RR 0.33, 95% CI 0.06 to 1.97; two trials, N = 98; I² = 0%; very low quality evidence), or reduces the incidence of OHSS (RR 7.07, 95% CI 0.42 to 117.81; two trials, N = 53; very low quality evidence) when compared to uFSH. </p> <p><b>Gonadotrophins versus continued clomiphene citrate</b> </p> <p>Gonadotrophins resulted in more live births than continued clomiphene citrate (RR 1.24, 95% CI 1.05 to 1.46; one trial, N = 661; I² = 0%; moderate‐quality evidence). This suggests that for a woman with a live birth rate of 41% with continued clomiphene citrate, the live birth rate with FSH was between 43% and 60%. There is probably little or no difference in the incidence of multiple pregnancy between treatments (RR 0.89, 95% CI 0.33 to 2.44; one trial, N = 661; I² = 0%; moderate‐quality evidence). Gonadotrophins resulted in more clinical pregnancies than continued clomiphene citrate (RR 1.31, 95% CI 1.13 to 1.52; one trial, N = 661; I² = 0%; moderate‐quality evidence), and more miscarriages (RR 2.23, 95% CI 1.11 to 4.47; one trial, N = 661; I² = 0%; moderate‐quality evidence). None of the women developed OHSS. </p> </section> <section id="CD010290-sec-0007"> <h3 class="title" id="CD010290-sec-0007">Authors' conclusions</h3> <p>There may be little or no difference in live birth, incidence of multiple pregnancy, clinical pregnancy rate, or miscarriage rate between urinary‐derived gonadotrophins and recombinant follicle stimulating hormone in women with polycystic ovary syndrome. For human menopausal gonadotropin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone we are uncertain whether one or the other improves or lowers live birth, incidence of multiple pregnancy, clinical pregnancy rate, or miscarriage rate. We are uncertain whether any of the interventions reduce the incidence of ovarian hyperstimulation syndrome. We suggest weighing costs and convenience in the decision to use one or the other gonadotrophin. In women with clomiphene citrate failure, gonadotrophins resulted in more live births than continued clomiphene citrate without increasing multiple pregnancies. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010290-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010290-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010290-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010290-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010290-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010290-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010290-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD010290-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010290-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010290-abs-0005" lang="en"> <h3>Gonadotrophins to induce ovulation in women with polycystic ovary syndrome (PCOS)</h3> <p><b>Review question</b> </p> <p>To compare the effectiveness and safety of gonadotrophins, hormones that regulate the reproductive system, as a second‐line treatment to stimulate ovulation in women with PCOS who do not ovulate or conceive on clomiphene citrate. </p> <p><b>Background</b> </p> <p>Infertility due to ovulation disorders is the most common reason for women to seek counselling or treatment. These women are treated by stimulating ovulation with medication, so‐called 'ovulation induction'. This is usually done with tablets containing clomiphene citrate, as the first line of treatment. If women do not react to this medication, the most common second‐line treatment in these women is ovulation induction with gonadotrophins, which are injectable drugs. Various types of gonadotrophin have been developed: urinary‐derived products, available in purified (FSH‐P), and highly purified (FSH‐HP) form, and human menopausal gonadotrophin, also available in highly purified form (HP‐HMG). Finally, recombinant FSH (rFSH) was developed artificially to obtain even higher purity. </p> <p>Women who do react, but do not conceive within six ovulatory clomiphene citrate cycles, may continue with clomiphene citrate or switch to gonadotrophins. </p> <p><b>Study characteristics</b> </p> <p>The review includes 15 trials, covering 2387 women. Ten trials compared urinary‐derived gonadotrophins with rFSH. Of these, three trials compared rFSH with human menopausal gonadotrophin, and seven trials compared rFSH with FSH‐HP. Four trials compared FSH‐P with human menopausal gonadotrophin. One trial compared gonadotrophins with continued clomiphene citrate. We found no trials that compared rFSH with FSH‐P, or FSH‐HP with FSH‐P. The evidence is current to January 2018. </p> <p><b>Key results</b> </p> <p>There may be little or no difference in live birth, multiple pregnancy, clinical pregnancy, or miscarriage rate between urinary‐derived gonadotrophins and recombinant FSH. We are uncertain whether human menopausal gonadotrophin or urinary follicle stimulating hormone improves pregnancy outcomes in women with PCOS. We are uncertain whether the interventions decrease the incidence of ovarian hyperstimulation syndrome. </p> <p>When compared to continued treatment with clomiphene citrate, gonadotrophins resulted in more live births without increasing the rate of multiple pregnancies. Gonadotrophins resulted in more clinical pregnancies, but also in more miscarriages than clomiphene citrate, while there were no cases of ovarian hyperstimulation syndrome. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was low to very low for outcomes from rFSH versus urinary gonadotrophins, and human menopausal gonadotrophin versus FSH‐P. The quality of the evidence was moderate for outcomes from gonadotrophins versus continued clomiphene citrate. </p> <p>Ten of the fifteen studies included in this review reported a commercial sponsor.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010290-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010290-sec-0112"></div> <h3 class="title" id="CD010290-sec-0113">Implications for practice</h3> <section id="CD010290-sec-0113"> <p>There may be little or no difference in live birth, incidence of multiple pregnancy, clinical pregnancy rate, or miscarriage rate between urinary‐derived gonadotrophins and recombinant follicle stimulating hormone in women with polycystic ovary syndrome. For human menopausal gonadotropin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone we are uncertain wether one or the other improves or lowers live birth, incidence of multiple pregnancy, clinical pregnancy rate, or miscarriage rate. We are uncertain whether any of the interventions reduce the incidence of ovarian hyperstimulation syndrome. We suggest weighing costs and convenience in the decision to use one or the other gonadotrophin. In women with clomiphene citrate failure, gonadotrophins resulted in more live births than continued clomiphene citrate without increasing multiple pregnancies. </p> </section> <h3 class="title" id="CD010290-sec-0114">Implications for research</h3> <section id="CD010290-sec-0114"> <p>New research on the effectiveness of gonadotrophins should be specifically directed at preventing multiple pregnancies while retaining the highest live birth chances. Another reason for the need for new research is the high risk of bias in most of the included studies in this review. To reduce the risk of performance and detection bias, future trials should implement blinding of study participants, personnel, and outcome assessors. We need trials that study ovulation induction with letrozole in clomiphene citrate‐resistant women, or ovulation induction with letrozole to treat naive women over 12 cycles. We also need to study the effect of body mass index on the effectiveness of all ovulation induction treatments. According to a network meta‐analysis, letrozole or clomiphene citrate plus metformin are most effective, specifically in obese women (<a href="./references#CD010290-bbs2-0053" title="WangR , KimBV , vanWelyM , JohnsonNP , CostelloMF , ZhangH , et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta‐analysis. BMJ2017;356:j138. [doi: https://doi.org/10.1136/bmj.j138] ">Wang 2017</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010290-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010290-sec-0036"></div> <div class="table" id="CD010290-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Recombinant follicle stimulating hormone versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Recombinant follicle stimulating hormone versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women with polycystic ovarian syndrome (PCOS) undergoing ovulation induction<br/> <b>Settings:</b> women visiting the outpatient clinic<br/> <b>Intervention:</b> recombinant follicle stimulating hormone (rFSH) </p> <p><b>Comparison</b>: urinary‐derived gonadotrophins </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with urinary‐derived gonadotrophins</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with rFSH </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000<br/> (130 to 279) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.21<br/> (0.83 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>505<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of multiple pregnancy (per woman)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (14 to 48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.46 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000<br/> (210 to 303) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05<br/> (0.88 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1330<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (33 to 95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 <br/> (0.71 to 2.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of OHSS per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (12 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.48 <br/> (0.82 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1565<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>* The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OHSS:</b> ovarian hyperstimulation syndrome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision around the absolute effect<br/> <sup>b</sup>Downgraded one level for inconsistency in results across studies<br/> <sup>c</sup>Downgraded one level for inconsistent definition or for the lack of definition of OHSS </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010290-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone for ovulation induction in women with polycystic ovarian syndrome</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone for ovulation induction in women with polycystic ovarian syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women with polycystic ovarian syndrome (PCOS) undergoing ovulation induction<br/> <b>Settings:</b> women visiting the outpatient clinic<br/> <b>Intervention:</b> Human menopausal gonadotrophin (HMG) or highly purified HMG </p> <p><b>Comparison</b>: urinary follicle stimulating hormone (uFSH) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with uFSH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HMG or HP‐HMG </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000<br/> (117 to 452) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.28</p> <p>(0.65 to 2.52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of multiple pregnancy (per woman)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (12 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.13<br/> (0.51 to 8.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000<br/> (134 to 527) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.31<br/> (0.66 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (5 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/> (0.06 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of OHSS per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4/28 <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 7.07<br/> (0.42 to 117.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OHSS:</b> ovarian hyperstimulation syndrome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgarded two levels for serious imprecision around the absolute effect (wide CI and small sample size)<br/> <sup>b</sup>Downgraded one level for inconsistency in results across studies<br/> <sup>c</sup>Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the control group </p> <p><sup>d</sup> Downgraded one level for inconsistent definition or for the lack of definition of OHSS; two of four studies did not report this outcome </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010290-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gonadotrophins compared to continued clomiphene citrate for ovulation induction</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Gonadotrophins compared to continued clomiphene citrate for ovulation induction </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anovulatory women with clomiphene citrate‐failure<br/> <b>Setting:</b> women visiting the outpatient clinic<br/> <b>Intervention:</b> gonadotrophins<br/> <b>Comparison:</b> continued clomiphene citrate (CC) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with continued CC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gonadotrophins</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>512 per 1000<br/> (434 to 603) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (1.05 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of multiple pregnancy per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (8 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.33 to 2.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>584 per 1000<br/> (504 to 678) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.31<br/> (1.13 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriages per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (37 to 147) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.23<br/> (1.11 to 4.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference when expressed per clinical pregnancy</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of OHSS per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OHSS:</b> ovarian hyperstimulation syndrome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias – no blinding performed </p> <p><sup>b</sup> Downgraded one level for imprecision in result </p> <p><sup>c</sup> Downgraded one level for inconsistency in outcome, i.e. there were more clinical pregnancies in the gonadotrophin group; there may be little or no difference when expressing miscarriage per clinical pregnancy </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010290-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010290-sec-0037"></div> <section id="CD010290-sec-0038"> <h3 class="title" id="CD010290-sec-0038">Description of the condition</h3> <p>Subfertility occurs in one in 10 couples world‐wide. In about one‐third of couples, this is based on polycystic ovary syndrome (PCOS). PCOS is characterised by oligo‐anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries (<a href="./references#CD010290-bbs2-0049" title="Rotterdam ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41‐7. ">Rotterdam consensus group 2004a</a>; <a href="./references#CD010290-bbs2-0050" title="Rotterdam ESHRE/ASRM‐Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome. Fertility and Sterility2004;81(1):19‐25. ">Rotterdam consensus group 2004b</a>). The syndrome affects approximately 6% to 10% of women of childbearing age. </p> <p>Infertility due to chronic anovulation is the most common reason for women with PCOS to seek counselling or treatment. First line treatment for these women is ovulation induction with clomiphene citrate, with or without metformin. A recent review showed that letrozole is an effective alternative to clomiphene citrate (<a href="./references#CD010290-bbs2-0033" title="FranikS , KremerJA , NelenWL , FarquharC . Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2018, Issue 5. [DOI: 10.1002/14651858.CD010287.pub3] ">Franik 2018</a>). </p> <p>About 20% of women do not ovulate on clomiphene citrate, and require alternative or second‐line ovulation induction strategies. This failure to ovulate with clomiphene citrate is termed ‘clomiphene resistance’. The most common treatment in women with clomiphene citrate‐resistant PCOS is ovulation induction with gonadotrophins (<a href="./references#CD010290-bbs2-0028" title="BalenAH . Ovulation induction in the management of anovulatory polycystic ovary syndrome. Molecular and Cellular Endocrinology2013;373(1‐2):77‐82. ">Balen 2013</a>), or laparoscopic electrocautery of the ovaries as an effective alternative treatment (<a href="./references#CD010290-bbs2-0032" title="FarquharC , BrownJ , MarjoribanksJ . Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD001122.pub4] ">Farquhar 2012</a>). </p> <p>Of the women ovulating on clomiphene citrate, only half of these women conceive within six months of treatment leads. If women fail to conceive with clomiphene citrate, despite regular ovulatory cycles, the term ‘clomiphene‐failure’ is used. Also in these women, clomiphene citrate or letrozole treatment is often changed to second‐line ovulation induction with gonadotrophins. </p> </section> <section id="CD010290-sec-0039"> <h3 class="title" id="CD010290-sec-0039">Description of the intervention</h3> <p>The strategy of stimulating follicle development and growth with exogenous gonadotrophins for ovulation induction in women with clomiphene citrate‐resistant PCOS or clomiphene citrate‐failure is well established. </p> <p>Follicle‐stimulating hormone (FSH) is found in the pituitary gland, and circulates in the bloodstream in various molecular forms. This molecular heterogeneity is due to the variation in the structures of the carbohydrate moieties, in particular of sialic acid. It is the configuration of these carbohydrate moieties that determines the FSH isoform. The configuration depends on which glycosylation enzymes are available in the cell during synthesis (<a href="./references#CD010290-bbs2-0054" title="WideL . Isoforms of human gonadotrophins under different physiological conditions. In: KahnJA editor(s). Gonadotrophin Isoforms: Facts and Future. Copenhagen: Ciconia Foundation, 1997:43‐8. ">Wide 1997</a>). Each molecular glycoform has a different molecular weight, net charge, circulating half‐life, and metabolic clearance (<a href="./references#CD010290-bbs2-0027" title="BaenzigerJU , GreenED . Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of asparagine‐linked oligosaccharides on lutropin, follitropin and thyrotropin. Biochimica et Biophysica Acta1988;947(2):287‐306. ">Baenziger 1988</a>; <a href="./references#CD010290-bbs2-0037" title="GrayCJ . Glycoprotein gonadotrophins. Structure and synthesis. Acta Endocrinologica. Supplementum1988;288:20‐7. ">Gray 1988</a>; <a href="./references#CD010290-bbs2-0051" title="Stockell HartreeAS , RenwickAG . Molecular structures of glycoprotein hormones and functions of their carbohydrate components. Biochemical Journal1992;287(Part 3):665‐79. ">Stockell Hartree 1992</a>; <a href="./references#CD010290-bbs2-0055" title="WilsonCA , LeighAJ , ChapmanAJ . Gonadotrophin glycosylation and function. Journal of Endocrinology1990;125(1):3‐14. ">Wilson 1990</a>). Gonadotrophins were originally extracted from pituitary glands (<a href="./references#CD010290-bbs2-0034" title="Gemzell CA ,  DiczfalusyE ,  TillingerG . Clinical effect of human pituitary follicle‐stimulating hormone (FSH). Journal of Clinical Endocrinology and Metabolism1958;18(12):1333‐48. ">Gemzell 1958</a>), and later from the urine of postmenopausal women (<a href="./references#CD010290-bbs2-0046" title="LunenfeldB , MenziA , VoletB . Clinical effects of a human postmenopausal gonadotropin. La Rassegna di Clinica, Terapia e Scienze Affini1960;59:213‐6. ">Lunenfeld 1960</a>). </p> <p>Over the last five decades, various urinary‐derived FSH products, or urofollitropins, have been developed. Menotropin (human menopausal gonadotrophin) has been available since the early 1960s and contains FSH, luteinising hormone (LH) and large quantities of potentially allergenic urinary proteins. Purified urofollitropin has been available since the mid‐1980s. Purified FSH is devoid of LH, but still contains urinary proteins. Highly purified urofollitropin has been available since the mid‐1990s and contains very small amounts of urinary proteins. The absence of urinary proteins reduces rare adverse reactions, such as local allergy or hypersensitivity (<a href="./references#CD010290-bbs2-0025" title="AlbanoC , SmitzJ , CamusM , Coelingh BenninkH , VanSteirteghemAC , DevroeyP . Pregnancy and birth in an in‐vitro fertilization cycle after controlled ovarian stimulation in a women with a history of allergic reaction to human menopausal gonadotrophin. Human Reproduction1996;11(8):1632‐4. ">Albano 1996</a>; <a href="./references#CD010290-bbs2-0030" title="BiffoniM , BattagliaA , BorrelliF , CantelmoA , GalliG , EshkolA . Allergenic potential of gonadotrophic preparations in experimental animal: Relevance of purity. Human Reproduction1994;9(10):1845‐8. ">Biffoni 1994</a>). The most recent development in urinary gonadotrophins is highly purified menotropin (highly purified human menopausal gonadotrophin), containing equal amounts of FSH and LH activity. </p> <p>To obtain even higher purity, gonadotrophins were developed with recombinant DNA technology (recombinant FSH) in 1988 (<a href="./references#CD010290-bbs2-0041" title="HowlesCM . Genetic engineering of human FSH (Gonal F). Human Reproduction Update1996;2(2):172‐91. ">Howles 1996</a>; <a href="./references#CD010290-bbs2-0043" title="KeeneJL , MatzukMM , OtaniT , FauserBC , GalwayAB , HsuehAJ , et al. Expression of biologically active human follitropin in Chinese hamster ovary cells. Journal of Biological Chemistry1989;264(9):4769‐75. ">Keene 1989</a>). The production of recombinant FSH is independent of urine collection, thus guaranteeing a high availability of a biochemical pure FSH preparation that is free from LH and urinary protein contaminants. The production process also yields FSH with high specific bioactivity (roughly 100 times higher than for urine‐derived FSH products), minimal batch‐to‐batch discrepancies (<a href="./references#CD010290-bbs2-0029" title="BerghC . What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone. Human Reproduction1999;14(6):1418‐20. ">Bergh 1999</a>), and low immunogenicity. There is evidence that recombinant FSH has a higher bioactivity than urinary products (<a href="./references#CD010290-bbs2-0026" title="AndersenCY , WestergaardLG , VanWelyM . FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect?. Reproductive Biomedicine Online2004;9(2):231‐6. ">Andersen 2004</a>). </p> <p>At present, two preparations of recombinant FSH are available: follitropin alpha and follitropin beta. Both preparations are similar to pituitary and urinary FSH, although they show minor differences in the structure of the carbohydrate side chains, and contain more basic and fewer acidic isohormones than the urinary‐derived gonadotrophin preparations (<a href="./references#CD010290-bbs2-0031" title="DeLeeuwR , MuldersJ , VoortmanG , RomboutF , DammJ , KloosterboerL . Structure‐function relationship of recombinant follicle stimulating hormone (Puregon). Molecular Human Reproduction1996;2(5):361‐9. ">De Leeuw 1996</a>; <a href="./references#CD010290-bbs2-0038" title="HardK , MekkingA , DammJB , KamerlingJP , DeBoerW , WijnandsRA , et al. Isolation and structure determination of the intact sialylated N‐linked carbohydrate chains of recombinant human follitropin (hFSH) expressed in Chinese hamster ovary cells. European Journal of Biochemistry1990;193(1):263‐71. ">Hard 1990</a>; <a href="./references#CD010290-bbs2-0044" title="LambertA , RodgersM , MitchellR , WoodAM , WardleC , HiltonB , et al. In‐vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin‐HP. Human Reproduction1995;10(7):1928‐35. ">Lambert 1995</a>). </p> <p>Continued clomiphene citrate is taken for five days at the dose on which the woman ovulates. This is usually 50 mg, 100 mg, or 150 mg. </p> </section> <section id="CD010290-sec-0040"> <h3 class="title" id="CD010290-sec-0040">How the intervention might work</h3> <p>In the follicular phase of an ovulatory menstrual cycle, between 10 and 20 antral follicles develop. Of this cohort, one follicle will obtain dominance over the others, and will continue to grow until ovulation. In women with PCOS, this dominance does not occur. The aim of ovulation induction is to induce growth of preferably one follicle, and not more than three follicles. This can be accomplished by ovulation induction with gonadotrophins. Too forceful a regimen will result in overstimulation. and hence, in an increased risk of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS); a stimulation regimen with too low a dosage of gonadotrophins will not result in a dominant follicle, and thereby, will not lead to ovulation. </p> </section> <section id="CD010290-sec-0041"> <h3 class="title" id="CD010290-sec-0041">Why it is important to do this review</h3> <p>Gonadotrophins are the standard drugs in medical ovulation induction for women with PCOS, who did not ovulate or conceive on clomiphene citrate. In women who do ovulate on clomiphene citrate, continued clomiphene citrate for another six cycles is an option. Knowlegde on effectiveness and safety of these treatment options will enable informed treatment decisions. The present review is an update and extension of two previous Cochrane reviews (<a href="./references#CD010290-bbs2-0058" title="BayramN , VanWelyM , Van DerVeenF . Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD002121.pub2] ">Bayram 2001</a>; <a href="./references#CD010290-bbs2-0059" title="NugentD , VanderkerchoveP , HughesE , ArnotM , LilfordR . Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2000, Issue 4. [DOI: 10.1002/14651858.CD000410.pub2] ">Nugent 2000</a>). <a href="./references#CD010290-bbs2-0058" title="BayramN , VanWelyM , Van DerVeenF . Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD002121.pub2] ">Bayram 2001</a> compared rFSH with purified FSH and highly purified FSH; <a href="./references#CD010290-bbs2-0059" title="NugentD , VanderkerchoveP , HughesE , ArnotM , LilfordR . Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2000, Issue 4. [DOI: 10.1002/14651858.CD000410.pub2] ">Nugent 2000</a> compared human menopausal gonadotrophin with purified FSH. No Cochrane review has yet compared human menopausal gonadotrophin with recombinant FSH in clomiphene citrate‐resistant women. Summarising the evidence on the effectiveness and safety of the various gonadotrophins will help gynaecologists and women to make informed decisions on the best regimen for ovulation induction. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010290-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010290-sec-0042"></div> <p>To compare the effectiveness and safety of gonadotrophins as a second‐line treatment for ovulation induction in women with clomiphene citrate‐resistant polycystic ovary syndrome (PCOS), and women who do not ovulate or conceive after clomiphene citrate. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010290-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010290-sec-0043"></div> <section id="CD010290-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010290-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials. We excluded quasi‐randomised controlled trials in which allocation was, for example, by alternation, reference to case record numbers, or to dates of birth. We also excluded cross‐over trials, which are not appropriate in this context (<a href="./references#CD010290-bbs2-0052" title="VailA , GardenerE . Common statistical errors in the design and analysis of subfertility trials. Human Reproduction2003;18(5):1000‐4. ">Vail 2003</a>). </p> </section> <section id="CD010290-sec-0046"> <h4 class="title">Types of participants</h4> <p> <ol id="CD010290-list-0001"> <li> <p>Subfertile women with clomiphene citrate‐resistant PCOS undergoing ovulation induction. We defined clomiphene citrate‐resistance as a failure to ovulate with clomiphene citrate doses of at least 100 mg/day for at least five days. </p> </li> <li> <p>Subfertile women with PCOS and clomiphene citrate‐failure undergoing ovulation induction. We defined clomiphene citrate‐failure as a failure to conceive after three cycles of ovulation induction with clomiphene citrate. </p> </li> <li> <p>Women with prior treatment with metformin with or without clomiphene citrate.</p> </li> <li> <p>Women with prior treatment with electrocautery of the ovaries.</p> </li> </ol> </p> </section> <section id="CD010290-sec-0047"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD010290-list-0002"> <li> <p>Ovulation induction with recombinant follicle‐stimulating hormone (FSH) versus any other urinary gonadotrophin (human menopausal gonadotrophin, purified FSH, highly purified FSH) </p> </li> <li> <p>Ovulation induction with highly purified FSH versus purified FSH</p> </li> <li> <p>Ovulation induction with human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus purified FSH or highly purified FSH </p> </li> <li> <p>Ovulation induction with gonadotrophins or continued clomiphene citrate</p> </li> </ol> </p> <p>For all interventions, ovulation induction could be followed by intercourse or intrauterine insemination. We excluded trials involving co‐treatment with clomiphene citrate, metformin, luteinising hormone, letrozole or different gonadotrophins. </p> </section> <section id="CD010290-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD010290-sec-0049"> <h5 class="title">Primary outcomes</h5> <p>1. Live birth rate per woman</p> <p>2. Multiple pregnancy per woman</p> </section> <section id="CD010290-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p>3. Clinical pregnancy rate (per woman)</p> <p>4. Miscarriage rate (per woman) or miscarriages per woman</p> <p>5. Incidence of ovarian hyperstimulation syndrome (OHSS; (per woman))</p> <p>6. Total gonadotrophin dose per woman (IU)</p> <p>7. Total duration of stimulation per woman</p> </section> </section> </section> <section id="CD010290-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>This review has drawn on the search strategy developed for the Cochrane Gynaecology and Fertility group (CGF) as a whole. </p> <section id="CD010290-sec-0052"> <h4 class="title">Electronic searches</h4> <p>Marian Showell (CGF Group Information Specialist) developed the search strategies. See <a href="./appendices#CD010290-sec-0118">Appendix 1</a>, <a href="./appendices#CD010290-sec-0119">Appendix 2</a><a href="./appendices#CD010290-sec-0120">Appendix 3</a>, <a href="./appendices#CD010290-sec-0121">Appendix 4</a>, <a href="./appendices#CD010290-sec-0122">Appendix 5</a>, <a href="./appendices#CD010290-sec-0123">Appendix 6</a>. </p> <p>1) We searched the following electronic sources:</p> <p> <ul id="CD010290-list-0003"> <li> <p>Cochrane Gynaecology and Fertility Group specialised Register of Controlled Trials (searched 15 January 2018; <a href="./appendices#CD010290-sec-0118">Appendix 1</a>) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL Register of Studies Online (CRSO; searched 15 January 2018; <a href="./appendices#CD010290-sec-0119">Appendix 2</a>)) </p> </li> <li> <p>MEDLINE (1946 to 15 January 2018; <a href="./appendices#CD010290-sec-0120">Appendix 3</a>) </p> </li> <li> <p>Embase (1980 to 15 January 2018; <a href="./appendices#CD010290-sec-0121">Appendix 4</a>) </p> </li> <li> <p>PsycINFO (1806 to 15 January 2018; <a href="./appendices#CD010290-sec-0122">Appendix 5</a>) </p> </li> <li> <p>CINAHL (1961 to 15 January 2018; <a href="./appendices#CD010290-sec-0123">Appendix 6</a>) </p> </li> </ul> </p> <p>2) Other electronic sources included:</p> <p> <ul id="CD010290-list-0004"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 15 January 2018) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>; searched 15 January 2018) </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database) and other Spanish and Portuguese language databases (<a href="http://pesquisa.bvsalud.org/portal/" target="_blank">pesquisa.bvsalud.org/portal/</a>; 1982 to 15 January 2018) </p> </li> <li> <p>OpenGrey for unpublished literature from Europe (<a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a>; searched 15 January 2018) </p> </li> </ul> </p> </section> <section id="CD010290-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We searched the following conference abstracts:</p> <p> <ul id="CD010290-list-0005"> <li> <p>American Society for Reproductive Medicine and Canadian Fertility and Andrology Society (ASRM/CFAS) Conjoint Annual Meeting (2001 to 2018), Abstracts of the Scientific Oral and Poster Sessions, Program Supplement; </p> </li> <li> <p>European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting (2001 to 2018), Abstracts of the Scientific Oral and Poster Sessions, Program Supplement. </p> </li> </ul> </p> <p>We handsearched the references cited in all obtained studies. We searched PubMed and Google for any recent trials that had not yet been indexed in MEDLINE. </p> <p>We asked Serono Benelux BV (Merck Group), Ferring, and IBSA, the manufacturers of gonadotrophins, for ongoing studies and unpublished data. </p> </section> </section> <section id="CD010290-sec-0054"> <h3 class="title" id="CD010290-sec-0054">Data collection and analysis</h3> <section id="CD010290-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Three review authors (NW, EK, and MvW) independently examined the electronic search results for reports of possibly relevant trials, and retrieved these reports in full. All review authors independently applied the selection criteria to the trial reports, rechecking trial eligibility and resolving disagreements by discussion with the other authors. </p> </section> <section id="CD010290-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (NW, EK, and MvW) independently extracted the outcome data and information on funding, location, clinical and design details, and participants. We resolved any differences by discussion. We entered details of the studies into the '<a href="./references#CD010290-sec-0133" title="">Characteristics of included studies</a>' table. We presented studies that appeared to meet the inclusion criteria but were excluded from the review in the '<a href="./references#CD010290-sec-0134" title="">Characteristics of excluded studies</a>' table, briefly stating the reason for exclusion, but giving no further information. </p> </section> <section id="CD010290-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (NW, EK, and MvW) extracted information regarding the risk of bias (threats to internal validity) under six domains (also see the Cochrane 'Risk of bias' assessment tool in <a href="./appendices#CD010290-sec-0124">Appendix 7</a>; (<a href="./references#CD010290-bbs2-0040" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>)). We resolved any differences by discussion. </p> <p>1. Sequence generation. Evidence that an unpredictable random process was used.</p> <p>2. Allocation concealment. Evidence that the allocation list was not available to anyone involved in the recruitment process. </p> <p>3. Blinding of participants, clinicians, and outcome assessors. Evidence that knowledge of allocation was not available to those involved in subsequent treatment decisions or follow‐up efforts. </p> <p>4. Completeness of outcome data. Evidence that any losses to follow‐up were low and comparable between groups. </p> <p>5. Selective outcome reporting. Evidence that major outcomes had been reported in sufficient detail to allow analysis, independently of their apparent statistical significance. </p> <p>6. Other potential sources. Evidence of miscellaneous errors or circumstances that might influence the internal validity of trial results. </p> <p>We sought missing details from the authors of the original publications. We present all details in the 'Risk of bias' table following each included study. </p> </section> <section id="CD010290-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised all binary outcomes using relative risk ratio (RR) with a 95% confidence interval (CI). In cases of no events, we also calculated a risk difference (RD) with a 95% CI. </p> <p>We treated ordinal scales, such as amount of gonadotrophin used and duration of ovarian stimulation, as continuous outcomes. We abstracted, calculated, or requested means and standard deviations and calculated the mean difference with 95% CI for these outcomes. </p> </section> <section id="CD010290-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>We expressed all outcomes per woman randomised, and multiple pregnancy per clinical pregnancy. </p> </section> <section id="CD010290-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>Where there was insufficient information in the published report, we attempted to contact the authors for clarification. If missing data became available, we included them in the analysis. We anticipated that trials conducted over 10 years ago might not have data on live birth rates. We analysed data extracted from the trials on an intention‐to‐treat basis. Where randomised participants were missing from outcome assessment, we contacted the authors for additional data. If further data were not available, we assumed that missing participants had failed to achieve pregnancy and had not suffered any of the reported adverse events. </p> </section> <section id="CD010290-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>The presence of statistical heterogeneity of treatment effect among trials was determined using the I² statistic (<a href="./references#CD010290-bbs2-0039" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). We considered whether clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by the measure of the I² statistic. We took an I² measurement greater than 50% to indicate substantial heterogeneity, in which case, we tested the effect of using a random‐effects model (<a href="./references#CD010290-bbs2-0040" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD010290-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies, and by being alert for duplication of data. If we had included 10 or more studies in an analysis, we had planned to use a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD010290-sec-0063"> <h4 class="title">Data synthesis</h4> <p>When multiple studies were available on a similar comparison, we used Review Manager 5.3 software to perform the meta‐analyses, using the Mantel‐Haenszel method with a fixed‐effect model (<a href="./references#CD010290-bbs2-0048" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). For reporting purposes, we translated primary outcomes to absolute risks. We combined results for continuous outcomes using the mean difference. </p> </section> <section id="CD010290-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If excessive heterogeneity existed within strata, we had planned to explore this informally using the clinical and design details recorded in the '<a href="./references#CD010290-sec-0133" title="">Characteristics of included studies</a>' table. </p> <p> <ul id="CD010290-list-0006"> <li> <p>Prospectively, we had planned to undertake three different stratifications of the primary outcomes: type of urinary gonadotrophin (human menopausal gonadotrophin, purified FSH and highly purified FSH); single or multiple cycles; sponsorship (commercial, non‐commercial (<a href="./references#CD010290-bbs2-0045" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ2003;326(7400):1167‐70. ">Lexchin 2003</a>)). </p> </li> </ul> </p> </section> <section id="CD010290-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made about study eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if: </p> <p> <ul id="CD010290-list-0007"> <li> <p>we had used a random‐effects model</p> </li> <li> <p>we had reported odds ratios rather than relative risk ratios</p> </li> </ul> </p> <section id="CD010290-sec-0066"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We generated 'Summary of findings' tables using GRADEpro software and Cochrane methods (<a href="./references#CD010290-bbs2-0036" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 17 May 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>; <a href="./references#CD010290-bbs2-0040" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011</a>). These tables present the overall quality of the body of evidence for main review outcomes (live birth, multiple pregnancy, clinical pregnancy, miscarriage, and OHSS) for the main review comparison (recombinant FSH versus urinary‐derived gonadotrophins) using GRADE criteria: study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness, and publication bias. We also presented tables for our other comparisons: human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary FSH, and gonadotrophins versus continued clomiphene citrate. We justified judgements about evidence quality (high, moderate or low), documented them, and incorporated them into the reporting of results for each outcome. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010290-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010290-sec-0067"></div> <section id="CD010290-sec-0068"> <h3 class="title">Description of studies</h3> <p>For details of the studies please see: <a href="./references#CD010290-sec-0133" title="">Characteristics of included studies</a>; <a href="./references#CD010290-sec-0134" title="">Characteristics of excluded studies</a> </p> <section id="CD010290-sec-0069"> <h4 class="title">Results of the search</h4> <p>For this update, we screened 588 titles and identified an additional five studies for eligibility assessment. From these five studies, we included one trial, we excluded two studies, and we listed two studies as studies awaiting classification. </p> <p>See <a href="#CD010290-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010290-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010290-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD010290-sec-0070"> <h4 class="title">Included studies</h4> <p>We included 15 trials in this update.</p> <p>1. Ten studies compared the effects of recombinant follicle‐stimulating hormone (rFSH) versus urinary derived gonadotrophins (human menopausal gonadotrophin: <a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>; urinary follicle‐stimulating hormone (uFSH): <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0012" title="SzilágyiA , BártfaiG , MánfaiA , KoloszárS , PálA , SzabóI . Low‐dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology2004;18(1):17‐22. ">Szilágyi 2004</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a> was described in a review on human gonadotrophins produced by recombinant DNA technology. The authors of the 2001 Cochrane Review collected the data for this trial by personal communication, and we used them again in this update (<a href="./references#CD010290-bbs2-0058" title="BayramN , VanWelyM , Van DerVeenF . Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD002121.pub2] ">Bayram 2001</a>). </p> <p>2. There were no studies that compared highly purified FSH with purified FSH.</p> <p>3. Four studies compared purified FSH with human menopausal gonadotrophin (<a href="./references#CD010290-bbs2-0004" title="GadirA , MofawiR , AlnaserH , AlrashidA , AloneziO , ShawR . Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology1990;33(5):585‐92. ">Gadir 1990</a>: <a href="./references#CD010290-bbs2-0007" title="McFaulP , TraubA , ThomsonW . Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1990;53(5):792‐7. ">McFaul 1990</a>; <a href="./references#CD010290-bbs2-0010" title="SagleM , Hamilton‐FairleyD , KiddyD , FranksS . A comparative, randomized study of low‐dose human menopausal gonadotropin and follicle‐stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility1991;55(1):56‐60. ">Sagle 1991</a>; <a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a>). <a href="./references#CD010290-bbs2-0004" title="GadirA , MofawiR , AlnaserH , AlrashidA , AloneziO , ShawR . Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology1990;33(5):585‐92. ">Gadir 1990</a> made an extra comparison with laparoscopic electrocautery of the ovaries.  </p> <p>4. One study compared gonadotrophins and continued clomiphene citrate during six cycles (<a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). </p> <p>One trial also included normo‐ovulatory women with unexplained subfertility (<a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>). For this review, we used only the data of women with polycystic ovary syndrome (PCOS). For <a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a>, we included pre‐cross‐over data. </p> <p>Eight trials reported data on live birth, and thirteen trials reported on multiple pregnancy (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0004" title="GadirA , MofawiR , AlnaserH , AlrashidA , AloneziO , ShawR . Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology1990;33(5):585‐92. ">Gadir 1990</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0007" title="McFaulP , TraubA , ThomsonW . Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1990;53(5):792‐7. ">McFaul 1990</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>; <a href="./references#CD010290-bbs2-0010" title="SagleM , Hamilton‐FairleyD , KiddyD , FranksS . A comparative, randomized study of low‐dose human menopausal gonadotropin and follicle‐stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility1991;55(1):56‐60. ">Sagle 1991</a>; <a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>; <a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). </p> <p>All studies that compared types of gonadotrophins included women who were clomiphene citrate‐resistant; seven of them also included women with clomiphene citrate‐failure (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). The study that compared gonadotrophins with continuous included only women with clomiphene citrate‐failure (<a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). None of the women included in this review had been treated with electrocautery in the past. Ten trials analysed more than one cycle per woman, whereas five trials only analysed one cycle per woman (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>). In four trials, intrauterine insemination was performed in some cases (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). All trials used a low‐dose step‐up protocol, but the protocol used in <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a> was unknown. Ten trials reported a commercial sponsor (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0010" title="SagleM , Hamilton‐FairleyD , KiddyD , FranksS . A comparative, randomized study of low‐dose human menopausal gonadotropin and follicle‐stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility1991;55(1):56‐60. ">Sagle 1991</a>; <a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a>; <a href="./references#CD010290-bbs2-0012" title="SzilágyiA , BártfaiG , MánfaiA , KoloszárS , PálA , SzabóI . Low‐dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology2004;18(1):17‐22. ">Szilágyi 2004</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). </p> <p>Six trials reported a power calculation (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>; <a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). </p> </section> <section id="CD010290-sec-0071"> <h4 class="title">Excluded studies</h4> <p>We excluded six trials: one trial because the outcome measure was the effect of FSH on haemostasis (<a href="./references#CD010290-bbs2-0020" title="RicciG , CernecaF , SimeoneR , PozzobonC , GuarnieriS , SartoreA , et al. Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open‐label, randomized, controlled trial. Human Reproduction2004;19(4):838‐48. ">Ricci 2004</a>); two studies because the outcome 'pregnancy' was not defined, and this outcome was only presented per cycle (<a href="./references#CD010290-bbs2-0016" title="HomburgR , EshelA , KilbornJ , AdamsJ , JacobsHS . Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for the treatment of infertility associated with polycystic ovaries. Human Reproduction1990;5(1):32‐5. ">Homburg 1990</a>; <a href="./references#CD010290-bbs2-0017" title="JacobsH , PorterR , EshelA , CraftI . Profertility uses of LHRH agonist analogues. In: VickeryBH , NestorJJJr editor(s). LHRH and its Analogues; Contraceptive and Therapeutic Application. Part 2. Lancaster: MTP Press, 1987:303‐22. ">Jacobs 1987</a>); one study because it was a cross‐over design, and it was not possible to extract the pre‐cross‐over data per woman (<a href="./references#CD010290-bbs2-0018" title="LarsenT , LarsenJF , SchiølerV , BostofteE , FeldingC . Comparison of urinary human follicle‐stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome. Fertility and Sterility1990;53(3):426‐31. ">Larsen 1990</a>); one study had the wrong intervention (cotreatment with clomiphene citrate (<a href="./references#CD010290-bbs2-0019" title="RashidiM , NajmiZ , MobasseriA . Advantages of recombinant follicle‐stimulating hormone over human menopausal gonadotropin in intrauterine insemination: a randomized clinical trial in polycystic ovary syndrome‐associated infertility. Gynecologic and Obstetric Investigation2016;81(2):118‐23. ">Rashidi 2016</a>)); and one study reported a wrong comparator (<a href="./references#CD010290-bbs2-0021" title="ZhouYZ , ShenH , ZuoWL , XuYH , DengXH , ChenYL , et al. A randomized, single‐blind, parallel‐controlled and multicentre study: compare the efficacy and safety of domestic and imported human recombinant FSH in WHO group II anovulatory infertility. Chung‐Hua Fu Chan Ko Tsa Chih (Chinese Journal of Obstetrics &amp; Gynecology)2016; Vol. 51, issue 4:258‐63. ">Zhou 2016</a>). </p> </section> </section> <section id="CD010290-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>We summarised the risks of bias in the included studies in <a href="#CD010290-fig-0002">Figure 2</a> and <a href="#CD010290-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010290-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010290-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD010290-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010290-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD010290-sec-0073"> <h4 class="title">Allocation</h4> <p>Allocation to the intervention or control group was adequately concealed in four trials (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). The allocation concealment was inadequate in two trials (<a href="./references#CD010290-bbs2-0004" title="GadirA , MofawiR , AlnaserH , AlrashidA , AloneziO , ShawR . Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology1990;33(5):585‐92. ">Gadir 1990</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>), and unclear in the remaining trials. </p> </section> <section id="CD010290-sec-0074"> <h4 class="title">Blinding</h4> <p>Four trials were assessor‐blinded (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>). Blinding was not performed in the remaining studies. </p> </section> <section id="CD010290-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>Two trials had a high risk of attrition bias (<a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a>; <a href="./references#CD010290-bbs2-0012" title="SzilágyiA , BártfaiG , MánfaiA , KoloszárS , PálA , SzabóI . Low‐dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology2004;18(1):17‐22. ">Szilágyi 2004</a>). For another two trials, this was unclear (<a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>). All other trials had a low risk of bias for this domain. </p> </section> <section id="CD010290-sec-0076"> <h4 class="title">Selective reporting</h4> <p>We rated six studies as having a low risk of selective reporting bias; eight as having an unclear risk of bias in this domain, and one study as having high risk (<a href="./references#CD010290-bbs2-0012" title="SzilágyiA , BártfaiG , MánfaiA , KoloszárS , PálA , SzabóI . Low‐dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology2004;18(1):17‐22. ">Szilágyi 2004</a>). </p> </section> <section id="CD010290-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>We rated this as unclear for all studies. Some studies provided too few details to make a judgement. Within all the trials, the baseline characteristics appeared balanced over the two treatment groups. Only six of the 15 trials mentioned the duration of the trial (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>; <a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). </p> </section> </section> <section id="CD010290-sec-0078"> <h3 class="title" id="CD010290-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD010290-tbl-0001"><b>Summary of findings for the main comparison</b> Recombinant follicle stimulating hormone versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome</a>; <a href="./full#CD010290-tbl-0002"><b>Summary of findings 2</b> Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone for ovulation induction in women with polycystic ovarian syndrome</a>; <a href="./full#CD010290-tbl-0003"><b>Summary of findings 3</b> Gonadotrophins compared to continued clomiphene citrate for ovulation induction</a> </p> <section id="CD010290-sec-0079"> <h4 class="title">1 Recombinant follicle‐stimulating hormone (rFSH) versus urinary‐derived gonadotrophins</h4> <section id="CD010290-sec-0080"> <h5 class="title">1.1 Live birth rate per woman</h5> <p>(<a href="#CD010290-fig-0004">Figure 4</a>; <a href="./references#CD010290-fig-0007" title="">Analysis 1.1</a>) </p> <div class="figure" id="CD010290-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.1 Live birth rate per woman by urinary gonadotrophins" data-id="CD010290-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.1 Live birth rate per woman by urinary gonadotrophins </p> </div> </div> </div> <p>Five trials, including 505 women, reported on live birth (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>; <a href="./references#CD010290-bbs2-0012" title="SzilágyiA , BártfaiG , MánfaiA , KoloszárS , PálA , SzabóI . Low‐dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology2004;18(1):17‐22. ">Szilágyi 2004</a>). After pooling the results, the overall risk ratio (RR) per woman was 1.21 (95% confidence interval (CI) 0.83 to 1.78; five RCTs, N = 505; I² = 9%, low‐quality evidence) indicating there may be little or no difference between the intervention and the comparison. Translated into absolute risks, this means that for a woman with a 16% chance of achieving a live birth with the use of urinary‐derived FSH, the chance of a live birth with the use of rFSH would be between 13% and 28%. Statistical heterogeneity for this outcome was low. The live birth rate varied from 16% to 40% in the rFSH group, and from 0% to 25% in the urinary gonadotrophin group. </p> <p>When we divided the urinary‐derived gonadotrophins into subgroups (three trials compared rFSH versus highly purified human menopausal gonadotrophin, two trials compared rFSH versus highly purified FSH), we found that there may be little or no difference between the subgroups (P = 0.10). The RR for rFSH versus highly purified human menopausal gonadotrophin or human menopausal gonadotrophin was 1.04 (95% CI 0.68 to 1.57; three RCTs, N = 409; I² = 0%; low‐quality evidence), and for rFSH versus highly purified FSH was 2.66 (95% CI 0.95 to 7.43; two RCTs, N = 96; I² = 11%; low‐quality evidence). </p> </section> <section id="CD010290-sec-0081"> <h5 class="title">1.2 Live birth rate per woman ‐ stratified by sponsor</h5> <p>All trials comparing rFSH and highly purified human menopausal gonadotrophin were sponsored by Ferring; the other two trials comparing rFSH and purified FSH did not report the sponsor. Therefore, subgrouped results per sponsor were similar to the gonadotrophin comparison, i.e. when we divided into subgroups, we found little or no difference between subgroups (P = 0.1; <a href="./references#CD010290-fig-0008" title="">Analysis 1.2</a>). </p> </section> <section id="CD010290-sec-0082"> <h5 class="title">1.3 Incidence of multiple pregnancy per woman</h5> <p>Eight studies, including 1368 women, reported on multiple pregnancy (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). There may be little or no difference in multiple pregnancy per woman between groups (RR 0.86, 95% CI 0.46 to 1.61; eight RCTs, N = 1368; I² = 0%; low‐quality evidence; <a href="./references#CD010290-fig-0009" title="">Analysis 1.3</a>). </p> <p>When we divided the urinary‐derived gonadotrophins into subgroups (three trials compared rFSH versus highly purified human menopausal gonadotrophin, five trials compared rFSH versus highly purified FSH), there was no evidence of a difference between the subgroups (P = 0.34). </p> </section> <section id="CD010290-sec-0083"> <h5 class="title">1.4 Incidence of multiple pregnancy per woman ‐ stratified per sponsor</h5> <p>When we subgrouped by sponsor, we found little or no difference between subgroups (P = 0.86; <a href="./references#CD010290-fig-0010" title="">Analysis 1.4</a>). </p> </section> <section id="CD010290-sec-0084"> <h5 class="title">1.5 Clinical pregnancy rate per woman</h5> <p>Eight studies, including 1330 women, reported on clinical pregnancy (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). There may be little or no difference in clinical pregnancy (RR 1.05, 95% CI 0.88 to 1.27; eight RCTs, N = 1330; I² = 0%; low‐quality evidence; <a href="./references#CD010290-fig-0011" title="">Analysis 1.5</a>). </p> <p>When we divided the urinary‐derived gonadotrophins into subgroups (three trials compared rFSH versus highly purified human menopausal gonadotrophin, five trials compared rFSH versus highly purified FSH), there was no evidence of a difference between the subgroups (P = 0.47). The RR for rFSH versus HP‐human menopausal gonadotrophin was 1.19 (95% CI 0.81 to 1.77, three RCTs, N = 409; I² = 0%; low‐quality evidence), and for rFSH versus highly purified FSH was 1.01 (95% CI 0.82 to 1.25; five RCTs, N = 921; I² = 0%; low‐quality evidence). </p> </section> <section id="CD010290-sec-0085"> <h5 class="title">1.6 Incidence of multiple pregnancy per clinical pregnancy</h5> <p>We found that there may be little or no difference in multiple pregnancy per clinical pregnancy (RR 0.75, 95% CI 0.43 to 1.32; eight RCTs, 315 pregnancies; I² = 0%; <a href="./references#CD010290-fig-0012" title="">Analysis 1.6</a>). </p> </section> <section id="CD010290-sec-0086"> <h5 class="title">1.7 Miscarriage rate per woman</h5> <p>Seven studies, including 970 women, reported on miscarriage (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0012" title="SzilágyiA , BártfaiG , MánfaiA , KoloszárS , PálA , SzabóI . Low‐dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology2004;18(1):17‐22. ">Szilágyi 2004</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). There may be little or no difference in miscarriage rate (RR 1.20, 95% CI 0.71 to 2.04; seven RCTs, N = 970; I² = 0%; low‐quality evidence; <a href="./references#CD010290-fig-0013" title="">Analysis 1.7</a>). </p> <p>When we divided the urinary‐derived gonadotrophins into subgroups (two trials compared rFSH versus highly purified human menopausal gonadotrophin, five trials compared rFSH versus highly purified FSH), we found no evidence of a difference between the subgroups (P = 0.71). </p> </section> <section id="CD010290-sec-0087"> <h5 class="title">1.8 Incidence of ovarian hyperstimulation syndrome (OHSS) per woman</h5> <p>(<a href="#CD010290-fig-0005">Figure 5</a>; <a href="./references#CD010290-fig-0014" title="">Analysis 1.8</a>) </p> <div class="figure" id="CD010290-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.8 Incidence of OHSS per woman by urinary gonadotrophins" data-id="CD010290-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.8 Incidence of OHSS per woman by urinary gonadotrophins </p> </div> </div> </div> <p>Ten studies, including 1565 women, reported OHSS (<a href="./references#CD010290-bbs2-0001" title="BalenA , PlatteauP , Nyboe AndersenA , DevroeyP , HelmgaardL , ArceJ . Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non‐inferiority trial. Human Reproduction2007;22(7):1816‐23. ">Balen 2007</a>; <a href="./references#CD010290-bbs2-0002" title="Coelingh BenninkH , FauserB , OutH . Recombinant follicle‐stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene‐resistant, normogonadotropic, chronic anovulation; a prospective, multicenter, assessor‐blind, randomized, clinical trial. Fertility and Sterility1998;69(1):19‐25. ">Coelingh Bennink 1998</a>; <a href="./references#CD010290-bbs2-0003" title="FeigenbaumSL , MillerP , KaufmannR , Elkind‐HirschK , FeinSH , MarshallDC . A new highly purified human‐derived FSH, Bravelle, is as effective and well tolerated as recombinant follitropin beta in ovulation induction in infertile women with ovulatory dysfunction. Today's Therapeutic Trends2001;19(4):297‐313. ">Feigenbaum 2001</a>; <a href="./references#CD010290-bbs2-0005" title="GerliS , CasiniML , UnferV , CostabileL , MignosaM , DiRenzoGC . Ovulation induction with urinary FSH or recombinant FSH in polycystic ovary syndrome patients: a prospective randomized analysis of cost‐effectiveness. Reproductive BioMedicine Online2004;9(5):494‐9. ">Gerli 2004</a>; <a href="./references#CD010290-bbs2-0006" title="LoumayeE , MartineauI , PiazziA , O'DeaL , InceS , HowlesC , et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Human Reproduction1996;11(1):95‐107. ">Loumaye 1996</a>; <a href="./references#CD010290-bbs2-0008" title="PlatteauP , Nyboe AndersenA , BalenA , DevroeyP , SørensenP , HelmgaardL , et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction2006;21(7):1798‐804. ">Platteau 2006</a>; <a href="./references#CD010290-bbs2-0009" title="RevelliA , PosoF , GennarelliG , MoffaF , GrassiG , MassobrioM . Recombinant versus highly‐purified, urinary follicle‐stimulating hormone (rFSH vs. HP‐uFSH) in ovulation induction: a prospective, randomized study with cost‐minimization analysis. Reproductive Biology and Endocrinology2006;4:38‐44. ">Revelli 2006</a>; <a href="./references#CD010290-bbs2-0012" title="SzilágyiA , BártfaiG , MánfaiA , KoloszárS , PálA , SzabóI . Low‐dose ovulation induction with urinary gonadotrophins or recombinant follicle stimulating hormone in patients with polycystic ovary syndrome. Gynaecological Endocrinology2004;18(1):17‐22. ">Szilágyi 2004</a>; <a href="./references#CD010290-bbs2-0013" title="TaketaniY , KellyE , YoshimuraY , HoshiaiH , IraharaM , MizunumaH , et al. Recombinant follicle stimulating hormone (follitropin alfa) versus purified urinary follicle stimulating hormone in a low dose step‐up regimen to induce ovulation in Japanese women with anti‐estrogen‐ineffective oligo‐ or anovulatory infertility. Reproductive Medicine and Biology2010;9:99‐106. ">Taketani 2010</a>; <a href="./references#CD010290-bbs2-0015" title="YaraliH , BukulmezO , GurganT . Urinary follicle‐stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate‐resistant, normogonadotropic, chronic anovulation: a prospective randomized study. Fertility and Sterility1999;72(2):276‐81. ">Yarali 1999</a>). After pooling the results, the overall RR for OHSS per woman was 1.48 (95% CI 0.82 to 2.65; 10 RCTs, N = 1565; I² = 0%; very low‐quality evidence), indicating we could not be certain whether rFSH reduced the incidence of OHSS (<a href="./references#CD010290-fig-0014" title="">Analysis 1.8</a>). This means that for a woman with a 2.2% chance of OHSS with the use of urinary‐derived gonadotrophins, the chance of OHSS with the use of rFSH would be between 1.2% and 9.6%. The OHSS rate varied from 0% to 20% in both groups. </p> <p>When we divided the urinary‐derived gonadotrophins into subgroups (three trials compared rFSH versus highly purified human menopausal gonadotrophin, seven trials compared rFSH versus highly purified FSH), we found no evidence of a difference between the subgroups (P = 0.53). The RR for rFSH versus highly purified human menopausal gonadotrophin was 1.11 (95% CI 0.39 to 3.20; three RCTs, N = 409; I² = 0%; very low‐quality evidence), and for rFSH versus highly purified FSH was 1.67 (95% CI 0.82 to 3.39; seven RCTs, N = 1156; I² = 0%; very low‐quality evidence). </p> </section> <section id="CD010290-sec-0088"> <h5 class="title">1.9 Mean total gonadotrophin dose per woman</h5> <p>We found that rFSH required a lower dose than urinary‐derived gonadotrophins to stimulate ovulation (MD ‐105.44 IU, 95% CI ‐154.21 to ‐56.68; six RCTs, N = 1046; I² = 81%). When we used a random‐effects model, in view of the high statistical heterogeneity, we found there may be little or no difference (MD ‐127.4 IU, 95% CI ‐258.06 to 3.26; <a href="./references#CD010290-fig-0015" title="">Analysis 1.9</a>). </p> </section> <section id="CD010290-sec-0089"> <h5 class="title">1.10 Total duration of stimulation per woman (days)</h5> <p>We found that rFSH required a shorter time to stimulate ovulation than urinary‐derived gonadotrophins (MD ‐0.66 days, 95% CI ‐1.04 to ‐0.28; six RCTs, N = 1122; I² = 72%). When we used a random‐effects model, in view of the high statistical heterogeneity, we found there may be little or no difference (MD ‐0.80 days, 95% CI ‐1.66 to 0.05; <a href="./references#CD010290-fig-0016" title="">Analysis 1.10</a>). </p> </section> </section> <section id="CD010290-sec-0090"> <h4 class="title">2 Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary FSH (uFSH) </h4> <section id="CD010290-sec-0091"> <h5 class="title">2.1 Live birth per woman</h5> <p>Three trials, including 138 women, reported on live birth (<a href="./references#CD010290-bbs2-0004" title="GadirA , MofawiR , AlnaserH , AlrashidA , AloneziO , ShawR . Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology1990;33(5):585‐92. ">Gadir 1990</a>; <a href="./references#CD010290-bbs2-0007" title="McFaulP , TraubA , ThomsonW . Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1990;53(5):792‐7. ">McFaul 1990</a>; <a href="./references#CD010290-bbs2-0010" title="SagleM , Hamilton‐FairleyD , KiddyD , FranksS . A comparative, randomized study of low‐dose human menopausal gonadotropin and follicle‐stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility1991;55(1):56‐60. ">Sagle 1991</a>). We are uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin improved live birth rate (RR 1.28, 95% CI 0.65 to 2.52; three RCTs, N = 138; I² = 0%; very low‐quality evidence; <a href="./references#CD010290-fig-0017" title="">Analysis 2.1</a>; <a href="#CD010290-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD010290-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2. Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), outcome: 2.1 Live birth rate per woman" data-id="CD010290-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2. Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), outcome: 2.1 Live birth rate per woman </p> </div> </div> </div> </section> <section id="CD010290-sec-0092"> <h5 class="title">2.2. Incidence of multiple pregnancy per woman</h5> <p>We are uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin led to a higher multiple pregnancy rate per woman (RR 2.13, 95% CI 0.51 to 8.91; four RCTs, N = 161; I² = 0%; very low‐quality evidence; <a href="./references#CD010290-fig-0018" title="">Analysis 2.2</a>). As two of the four studies had no multiple pregnancies, we also calculated the risk difference (RD 0.03, 95% CI ‐0.05 to 0.11). </p> </section> <section id="CD010290-sec-0093"> <h5 class="title">2.3 Incidence of multiple pregnancy per clinical pregnancy</h5> <p>We are uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin led to a higher multiple pregnancy rate per clinical pregnancy (RR 4.20, 95% CI 0.21 to 83.33; four RCTs, N = 161; I² = 0%; <a href="./references#CD010290-fig-0019" title="">Analysis 2.3</a>). As two of the four studies had no multiple pregnancies, we also calculated the risk difference (RD 0.11, 95% CI ‐0.22 to 0.45). </p> </section> <section id="CD010290-sec-0094"> <h5 class="title">2.4 Clinical pregnancy rate per woman</h5> <p>One study reported clinical pregnancy rate per woman (<a href="./references#CD010290-bbs2-0010" title="SagleM , Hamilton‐FairleyD , KiddyD , FranksS . A comparative, randomized study of low‐dose human menopausal gonadotropin and follicle‐stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility1991;55(1):56‐60. ">Sagle 1991</a>). <a href="./references#CD010290-bbs2-0007" title="McFaulP , TraubA , ThomsonW . Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1990;53(5):792‐7. ">McFaul 1990</a> presented pregnancy rates without defining this outcome. For this study, we calculated the clinical pregnancy rates by adding the number of live births to the number of miscarriages in each group. <a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a> reported conception rates, which we used as clinical pregnancy rate. After pooling the data, we are uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin improved clinical pregnancy rate (RR 1.31, 95% CI 0.66 to 2.59; three RCTs, N = 102; I² = 0%; very low‐quality evidence; <a href="./references#CD010290-fig-0020" title="">Analysis 2.4</a>). </p> </section> <section id="CD010290-sec-0095"> <h5 class="title">2.5 Miscarriage rate per woman</h5> <p>We are uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin reduced miscarriage rate (RR 0.33, 95% CI 0.06 to 1.97; two RCTs, N = 98; I² = 0%; very low‐quality evidence; <a href="./references#CD010290-fig-0021" title="">Analysis 2.5</a>). </p> </section> <section id="CD010290-sec-0096"> <h5 class="title">2.6 Incidence of OHSS per woman</h5> <p>Two studies, including 53 women, reported OHSS (<a href="./references#CD010290-bbs2-0010" title="SagleM , Hamilton‐FairleyD , KiddyD , FranksS . A comparative, randomized study of low‐dose human menopausal gonadotropin and follicle‐stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility1991;55(1):56‐60. ">Sagle 1991</a>; <a href="./references#CD010290-bbs2-0011" title="SeibelMM , McArdleC , SmithD , TaymorML . Ovulatoin induction in polycystic ovary syndrome with urinary follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1985;43(5):703‐7. ">Seibel 1985</a>). We are uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin reduced the incidence of OHSS (RR 7.07, 95% CI 0.42 to 117.81; two RCTs, N = 53; very low‐quality evidence; <a href="./references#CD010290-fig-0022" title="">Analysis 2.6</a>). </p> </section> <section id="CD010290-sec-0097"> <h5 class="title">2.7 Mean total gonadotrophin dose per woman</h5> <p><a href="./references#CD010290-bbs2-0004" title="GadirA , MofawiR , AlnaserH , AlrashidA , AloneziO , ShawR . Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology1990;33(5):585‐92. ">Gadir 1990</a> and <a href="./references#CD010290-bbs2-0007" title="McFaulP , TraubA , ThomsonW . Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1990;53(5):792‐7. ">McFaul 1990</a> reported mean values for total doses, but they did not state standard deviations. Mean total does for human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus uFSH were 1568 IU versus 1478 IU in <a href="./references#CD010290-bbs2-0004" title="GadirA , MofawiR , AlnaserH , AlrashidA , AloneziO , ShawR . Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clinical Endocrinology1990;33(5):585‐92. ">Gadir 1990</a>, and 1770 IU versus 1995 IU in <a href="./references#CD010290-bbs2-0007" title="McFaulP , TraubA , ThomsonW . Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1990;53(5):792‐7. ">McFaul 1990</a>. The authors reported that they found no significant difference between groups. </p> <p><a href="./references#CD010290-bbs2-0010" title="SagleM , Hamilton‐FairleyD , KiddyD , FranksS . A comparative, randomized study of low‐dose human menopausal gonadotropin and follicle‐stimulating hormone in women with polycystic ovarian syndrome. Fertility and Sterility1991;55(1):56‐60. ">Sagle 1991</a> also reported no significant difference between groups. They reported values in mean total dose per cycle: human menopausal gonadotrophin or highly purified human menopausal gonadotrophin 1080 IU (range: 525 to 1950 IU) versus uFSH 1447.5 IU (range: 675 to 2887.5 IU). </p> </section> <section id="CD010290-sec-0098"> <h5 class="title">2.8 Total duration of stimulation per woman (days)</h5> <p><a href="./references#CD010290-bbs2-0007" title="McFaulP , TraubA , ThomsonW . Treatment of clomiphene citrate‐resistant polycystic ovarian syndrome with pure follicle‐stimulating hormone or human menopausal gonadotropin. Fertility and Sterility1990;53(5):792‐7. ">McFaul 1990</a> reported no significant mean difference between human menopausal gonadotrophin (11.8 days) and uFSH (11.9 days). They did not provide standard deviations. </p> </section> </section> <section id="CD010290-sec-0099"> <h4 class="title">3 Gonadotrophins versus continued clomiphene citrate</h4> <p>One trial, including 661 women, measured all outcomes (<a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). </p> <section id="CD010290-sec-0100"> <h5 class="title">3.1 Live birth rate per woman</h5> <p>One trial, including 666 women reported on live birth (<a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). We found that gonadotrophins resulted in more live births than continued clomiphene citrate (RR 1.24, 95% CI 1.05 to 1.46; one trial, N = 661; moderate‐quality evidence; <a href="./references#CD010290-fig-0023" title="">Analysis 3.1</a>). This suggests that for a woman with a live birth rate of 41% with continued clomiphene citrate, the live birth rate with FSH was 43% to 60%. </p> </section> <section id="CD010290-sec-0101"> <h5 class="title">3.2. Incidence of multiple pregnancy per woman</h5> <p>There is probably little or no difference in the multiple pregnancy rate per woman (RR 0.89, 95% CI 0.33 to 2.44; one trial, N = 661; moderate‐quality evidence; <a href="./references#CD010290-fig-0024" title="">Analysis 3.2</a>). </p> </section> <section id="CD010290-sec-0102"> <h5 class="title">3.3 Incidence of multiple pregnancy per clinical pregnancy</h5> <p>There is probably little or no difference in the multiple pregnancy rate per clinical pregnancies (RR 0.68, 95% CI 0.25 to 1.84; one trial, N = 661, moderate‐quality evidence; <a href="./references#CD010290-fig-0025" title="">Analysis 3.3</a>). </p> </section> <section id="CD010290-sec-0103"> <h5 class="title">3.4 Clinical pregnancy rate per woman</h5> <p>Gonadotrophins resulted in more clinical pregnancies than continued clomiphene citrate (RR 1.31, 95% CI 1.13 to 1.52; one trial, N = 661; moderate‐quality evidence; <a href="./references#CD010290-fig-0026" title="">Analysis 3.4</a>). </p> </section> <section id="CD010290-sec-0104"> <h5 class="title">3.5 Miscarriage rate per woman</h5> <p>The number of miscarriages was higher in the group treated with gonadotrophins than in the clomiphene citrate group (RR 2.23, 95% CI 1.11 to 4.47; one trial, N = 661; low‐quality evidence). When expressed per clinical pregnancy, there was probably little or no difference in miscarriage rate (RR 1.70, 95% 0.86 to 3.36; <a href="./references#CD010290-fig-0027" title="">Analysis 3.5</a>) </p> </section> <section id="CD010290-sec-0105"> <h5 class="title">3.6 Incidence of OHSS per woman</h5> <p>OHSS did not occur in any of the women, therefore, we could not calculate the RR. The estimate for the risk difference was (0.00, 95% CI ‐0.01 to 0.01; one trial, N = 661; low‐quality evidence; <a href="./references#CD010290-fig-0028" title="">Analysis 3.6</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010290-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010290-sec-0106"></div> <section id="CD010290-sec-0107"> <h3 class="title" id="CD010290-sec-0107">Summary of main results</h3> <p>This review compared the effectiveness and safety of gonadotrophins as a second‐line treatment for ovulation induction in women with polycystic ovary syndrome (PCOS) who did not ovulate or conceive on clomiphene citrate. We found 10 studies that compared recombinant follicle‐stimulating hormone (rFSH) with urinary‐derived gonadotrophins, four trials that compared urinary FSH (uFSH) with human menopausal gonadotrophin, and one trial that compared gonadotrophins with continued clomiphene citrate. There may be little or no difference in pregnancy outcomes when rFSH was compared to urinary gonadotrophins as a whole. We are uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin improved pregnancy outcomes when compared with uFSH. We are uncertain whether there was any difference observed in ovarian hyperstimulation syndrome (OHSS) for any of the comparisons. We found no trials that compared rFSH and purified FSH, or highly purified FSH and purified FSH. The use of gonadotrophins resulted in higher live birth rates without increasing multiple pregnancy rates when compared to continued clomiphene citrate. </p> </section> <section id="CD010290-sec-0108"> <h3 class="title" id="CD010290-sec-0108">Overall completeness and applicability of evidence</h3> <p>For the trials that compared rFSH and urinary‐derived gonadotrophins, outcome data needed to make the planned comparisons were largely available; these trials were all published after 1996. The data from trials that compared rFSH and purified uFSH and highly purified uFSH were incomplete, probably because these trials had been published between 1985 and 1991, when there were no CONSORT or PRISMA guidelines, and clinical pregnancy or ovulation rates were still accepted endpoints. The outcome data for the gonadotrophin versus continued clomiphene citrate trial was complete. </p> <p>Seven trials did not define the outcome OHSS. The remaining studies used very different definitions (see <a href="./references#CD010290-sec-0133" title="">Characteristics of included studies</a>). It is common to categorise cases of OHSS by three degrees; mild, moderate, or severe (<a href="./references#CD010290-bbs2-0057" title="YoussefMA , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a>). Since this ranking was almost never used in the included studies of this review, it may be inappropriate to pool the data on OHSS. Also, different starting dosages were used, varying from 50 to 150 IU per day, with various criteria outlined to withhold an injection of human chorionic gonadotrophin. This may influence the incidence of OHSS, regardless of the type of gonadotrophin used. Nowadays, OHSS is not a common finding in ovulation induction. OHSS is mainly a complication that occurs after treatment with in vitro fertilisation (<a href="./references#CD010290-bbs2-0057" title="YoussefMA , Van derVeenF , Al‐InanyHG , MochtarMH , GriesingerG , Nagi MohesenM , et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD008046.pub4] ">Youssef 2014</a>). </p> <p>The data on gonadotrophin dose used and duration of stimulation were never presented per woman randomised, and showed high statistical heterogeneity. Therefore, these outcomes are likely to be biased, and one should not draw conclusions on the basis of these data. </p> <p>Four of the included studies comparing gonadotrophins used intrauterine insemination (IUI) in addition to ovulation induction with gonadotrophins. IUI may or may not have increased the pregnancy rate, but since these studies always provided IUI in both study arms, its effect on differential pregnancy rates was likely to be small. In the study comparing gonadotrophins with continued clomiphene citrate, women had also been randomised to IUI or intercourse. This study found little or no differences in the effect of IUI on any of the pregnancy outcomes (<a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a>). </p> <p>For the studies comparing gonadotrophins, the included population represented women with PCOS who were either clomiphene citrate‐resistant or had failed to conceive with clomiphene citrate. The evidence is broadly applicable as a second‐line treatment for ovulation induction in these women. The study comparing gonadotrophins and continued clomiphene citrate included only women who had ovulated on previous clomiphene citrate cycles but failed to conceive. </p> </section> <section id="CD010290-sec-0109"> <h3 class="title" id="CD010290-sec-0109">Quality of the evidence</h3> <p>Using GRADE assessment, we found that evidence for most outcomes was of low to very low quality, due to the limited number of studies comparing gonadotrophins, small study size, statistical heterogeneity, and the risk of bias in the individual studies. </p> <p>For the study comparing gonadotrophins with continuous clomiphene citrate, we assessed evidence for live birth and clinical pregnancy to be of moderate quality. </p> </section> <section id="CD010290-sec-0110"> <h3 class="title" id="CD010290-sec-0110">Potential biases in the review process</h3> <p>Strengths of this review include comprehensive systematic searching for eligible studies, rigid inclusion criteria for RCTs and data extraction, and independent analysis by three review authors. The possibility of publication bias was minimised by including both published and unpublished studies (such as abstracts from meetings). However, as with any review, we cannot guarantee that we found all eligible studies<i>.</i> </p> </section> <section id="CD010290-sec-0111"> <h3 class="title" id="CD010290-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in line with the outcomes of the previous Cochrane review of <a href="./references#CD010290-bbs2-0058" title="BayramN , VanWelyM , Van DerVeenF . Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD002121.pub2] ">Bayram 2001</a>, in concluding that rFSH and urinary‐derived gonadotrophins are equally effective for ovulation induction in women with PCOS, in terms of ovulation rate, pregnancy rate, miscarriage rate, and multiple pregnancy rate. Our results are also in line with the outcomes of the previous Cochrane Review of <a href="./references#CD010290-bbs2-0059" title="NugentD , VanderkerchoveP , HughesE , ArnotM , LilfordR . Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2000, Issue 4. [DOI: 10.1002/14651858.CD000410.pub2] ">Nugent 2000</a>, who concluded that comparing FSH and human menopausal gonadotrophin showed little or no difference in pregnancy rates. <a href="./references#CD010290-bbs2-0059" title="NugentD , VanderkerchoveP , HughesE , ArnotM , LilfordR . Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2000, Issue 4. [DOI: 10.1002/14651858.CD000410.pub2] ">Nugent 2000</a> did find a significant reduction in OHSS rate per cycle in women treated with purified FSH compared to human menopausal gonadotrophin. We focused on OHSS rate per woman, and found little or no difference, although only two trials were available for this analysis. </p> <p><a href="./references#CD010290-bbs2-0058" title="BayramN , VanWelyM , Van DerVeenF . Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD002121.pub2] ">Bayram 2001</a> and <a href="./references#CD010290-bbs2-0059" title="NugentD , VanderkerchoveP , HughesE , ArnotM , LilfordR . Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2000, Issue 4. [DOI: 10.1002/14651858.CD000410.pub2] ">Nugent 2000</a> did not evaluate the outcome of live birth. We found there may be little or no difference in live birth rate for the comparison of rFSH versus urinary gonadotrophins. We were uncertain whether human menopausal gonadotrophin or highly purified human menopausal gonadotrophin improved live birth rate when compared to uFSH. </p> <p>Another review compared rFSH with urinary‐derived FSH products (<a href="./references#CD010290-bbs2-0047" title="NahuisM , Van derVeenF , OosterhuisJ , MolBW , HompesP , VanWelyM . Review of the safety, efficacy, costs and patient acceptability of recombinant follicle‐stimulating hormone for injection in assisting ovulation induction in infertile women. International Journal of Women's Health2009;1:205‐11. ">Nahuis 2009</a>). The authors found that follitropin alpha, beta, and urinary FSH products appeared to be similarly effective in live birth rates, and clinical, ongoing, and multiple pregnancy rates. <a href="./references#CD010290-bbs2-0047" title="NahuisM , Van derVeenF , OosterhuisJ , MolBW , HompesP , VanWelyM . Review of the safety, efficacy, costs and patient acceptability of recombinant follicle‐stimulating hormone for injection in assisting ovulation induction in infertile women. International Journal of Women's Health2009;1:205‐11. ">Nahuis 2009</a> did not pool data on OHSS. </p> <p><a href="./references#CD010290-bbs2-0014" title="WeissNS , NahuisMJ , BordewijkE , OosterhuisJE , SmeenkJM , HoekA , et al. Gonadotrophins versus clomiphene citrate with or without intrauterine insemination in women with normogonadotropic anovulation and clomiphene failure (M‐OVIN): a randomised, two‐by‐two factorial trial. Lancet2018;391(10122):758–65. ">Weiss 2018</a> was the first to compare gonadotrophins and continuous clomiphene citrate in anovulatory women with clomiphene citrate‐failure. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010290-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010290-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010290-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010290-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.1 Live birth rate per woman by urinary gonadotrophins" data-id="CD010290-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.1 Live birth rate per woman by urinary gonadotrophins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.8 Incidence of OHSS per woman by urinary gonadotrophins" data-id="CD010290-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison 1. Recombinant FSH (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), outcome: 1.8 Incidence of OHSS per woman by urinary gonadotrophins </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2. Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), outcome: 2.1 Live birth rate per woman" data-id="CD010290-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 2. Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), outcome: 2.1 Live birth rate per woman </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 1 Live birth rate per woman by urinary gonadotrophins." data-id="CD010290-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 1 Live birth rate per woman by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 2 Live birth rate per woman by sponsor." data-id="CD010290-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 2 Live birth rate per woman by sponsor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 3 Multiple pregnancy per woman by urinary gonadotrophins." data-id="CD010290-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 3 Multiple pregnancy per woman by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 4 Multiple pregnancy per woman by sponsor." data-id="CD010290-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 4 Multiple pregnancy per woman by sponsor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 5 Clinical pregnancy rate per woman by urinary gonadotrophins." data-id="CD010290-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 5 Clinical pregnancy rate per woman by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 6 Incidence of multiple pregnancy per clinical pregnancy by urinary gonadotrophins." data-id="CD010290-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 6 Incidence of multiple pregnancy per clinical pregnancy by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 7 Miscarriage rate per woman by urinary gonadotrophins." data-id="CD010290-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 7 Miscarriage rate per woman by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 8 Incidence of OHSS per woman by urinary gonadotrophins." data-id="CD010290-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 8 Incidence of OHSS per woman by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 9 Total gonadotrophin dose per woman (IU) by urinary gonadotrophins." data-id="CD010290-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 9 Total gonadotrophin dose per woman (IU) by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 10 Total duration of stimulation per woman (days) by urinary gonadotrophins." data-id="CD010290-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins), Outcome 10 Total duration of stimulation per woman (days) by urinary gonadotrophins. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 1 Live birth rate per woman." data-id="CD010290-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 1 Live birth rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 2 Multiple pregnancy per woman." data-id="CD010290-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 2 Multiple pregnancy per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 3 Multiple pregnancy per clinical pregnancy." data-id="CD010290-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 3 Multiple pregnancy per clinical pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 4 Clinical pregnancy rate per woman." data-id="CD010290-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 4 Clinical pregnancy rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 5 Miscarriage rate per woman." data-id="CD010290-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 5 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 6 Incidence of OHSS per woman." data-id="CD010290-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH), Outcome 6 Incidence of OHSS per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 1 Live birth rate per woman." data-id="CD010290-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 1 Live birth rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 2 Multiple pregnancy per woman." data-id="CD010290-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 2 Multiple pregnancy per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 3 Multiple pregnancy (per clinical pregnancy)." data-id="CD010290-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 3 Multiple pregnancy (per clinical pregnancy). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 4 Clinical pregnancy per woman." data-id="CD010290-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 4 Clinical pregnancy per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 5 Miscarriages per woman." data-id="CD010290-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 5 Miscarriages per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010290-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/urn:x-wiley:14651858:media:CD010290:CD010290-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_t/tCD010290-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 6 Incidence of OHSS per woman." data-id="CD010290-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Gonadotrophins (FSH) versus continued clomiphene citrate (CC), Outcome 6 Incidence of OHSS per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/media/CDSR/CD010290/image_n/nCD010290-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010290-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Recombinant follicle stimulating hormone versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Recombinant follicle stimulating hormone versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women with polycystic ovarian syndrome (PCOS) undergoing ovulation induction<br/> <b>Settings:</b> women visiting the outpatient clinic<br/> <b>Intervention:</b> recombinant follicle stimulating hormone (rFSH) </p> <p><b>Comparison</b>: urinary‐derived gonadotrophins </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with urinary‐derived gonadotrophins</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with rFSH </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000<br/> (130 to 279) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.21<br/> (0.83 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>505<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of multiple pregnancy (per woman)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (14 to 48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.86<br/> (0.46 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1368<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>239 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000<br/> (210 to 303) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.05<br/> (0.88 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1330<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (33 to 95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20 <br/> (0.71 to 2.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of OHSS per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (12 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.48 <br/> (0.82 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1565<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>* The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OHSS:</b> ovarian hyperstimulation syndrome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision around the absolute effect<br/> <sup>b</sup>Downgraded one level for inconsistency in results across studies<br/> <sup>c</sup>Downgraded one level for inconsistent definition or for the lack of definition of OHSS </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Recombinant follicle stimulating hormone versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010290-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone for ovulation induction in women with polycystic ovarian syndrome</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b>Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone for ovulation induction in women with polycystic ovarian syndrome</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women with polycystic ovarian syndrome (PCOS) undergoing ovulation induction<br/> <b>Settings:</b> women visiting the outpatient clinic<br/> <b>Intervention:</b> Human menopausal gonadotrophin (HMG) or highly purified HMG </p> <p><b>Comparison</b>: urinary follicle stimulating hormone (uFSH) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with uFSH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with HMG or HP‐HMG </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>230 per 1000<br/> (117 to 452) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.28</p> <p>(0.65 to 2.52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of multiple pregnancy (per woman)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (12 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.13<br/> (0.51 to 8.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000<br/> (134 to 527) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.31<br/> (0.66 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (5 to 161) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/> (0.06 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of OHSS per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events <sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4/28 <sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 7.07<br/> (0.42 to 117.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>a,b,d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>* <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OHSS:</b> ovarian hyperstimulation syndrome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgarded two levels for serious imprecision around the absolute effect (wide CI and small sample size)<br/> <sup>b</sup>Downgraded one level for inconsistency in results across studies<br/> <sup>c</sup>Event rate derived from the raw data. A 'per thousand' rate is non‐informative in view of the scarcity of evidence and zero events in the control group </p> <p><sup>d</sup> Downgraded one level for inconsistent definition or for the lack of definition of OHSS; two of four studies did not report this outcome </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone for ovulation induction in women with polycystic ovarian syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010290-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gonadotrophins compared to continued clomiphene citrate for ovulation induction</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b>Gonadotrophins compared to continued clomiphene citrate for ovulation induction </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> anovulatory women with clomiphene citrate‐failure<br/> <b>Setting:</b> women visiting the outpatient clinic<br/> <b>Intervention:</b> gonadotrophins<br/> <b>Comparison:</b> continued clomiphene citrate (CC) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with continued CC</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with gonadotrophins</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>413 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>512 per 1000<br/> (434 to 603) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (1.05 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of multiple pregnancy per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (8 to 57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/> (0.33 to 2.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>584 per 1000<br/> (504 to 678) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.31<br/> (1.13 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriages per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (37 to 147) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.23<br/> (1.11 to 4.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There may be little or no difference when expressed per clinical pregnancy</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of OHSS per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>661<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>OHSS:</b> ovarian hyperstimulation syndrome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for risk of bias – no blinding performed </p> <p><sup>b</sup> Downgraded one level for imprecision in result </p> <p><sup>c</sup> Downgraded one level for inconsistency in outcome, i.e. there were more clinical pregnancies in the gonadotrophin group; there may be little or no difference when expressing miscarriage per clinical pregnancy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Gonadotrophins compared to continued clomiphene citrate for ovulation induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/full#CD010290-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010290-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate per woman by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.83, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.68, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [0.95, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Live birth rate per woman by sponsor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.83, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Ferring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.68, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [0.95, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Multiple pregnancy per woman by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.46, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.49, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Multiple pregnancy per woman by sponsor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.67, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Ferring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.49, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 MSD ‐ Organon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.68, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Merck ‐ Serono</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.14, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.19, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical pregnancy rate per woman by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.81, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Incidence of multiple pregnancy per clinical pregnancy by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.43, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.47, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.24, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Miscarriage rate per woman by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.71, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.24, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.71, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Incidence of OHSS per woman by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.82, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.39, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.82, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total gonadotrophin dose per woman (IU) by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐105.44 [‐154.21, ‐56.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐283.94 [‐449.10, ‐118.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐88.40 [‐139.44, ‐37.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total duration of stimulation per woman (days) by urinary gonadotrophins <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐1.04, ‐0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 rFSH versus HMG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.28 [‐3.49, ‐1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 rFSH versus uFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.88, ‐0.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Recombinant follicle stimulating hormone (rFSH) versus urinary‐derived gonadotrophins (u‐gonadotrophins)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010290-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.65, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Multiple pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [0.51, 8.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Multiple pregnancy per clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.2 [0.21, 83.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical pregnancy rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.66, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Incidence of OHSS per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.07 [0.42, 117.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Human menopausal gonadotrophin (HMG) or highly purified HMG (HP‐HMG) versus urinary FSH (uFSH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010290-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Gonadotrophins (FSH) versus continued clomiphene citrate (CC)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.05, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Multiple pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.33, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Multiple pregnancy (per clinical pregnancy) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.25, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical pregnancy per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.13, 1.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Miscarriages per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.11, 4.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Incidence of OHSS per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.01, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Gonadotrophins (FSH) versus continued clomiphene citrate (CC)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010290.pub3/references#CD010290-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010290.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010290-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010290-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010290-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD010290-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD010290-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD010290-note-0001">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010290-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010290\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010290\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010290\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010290\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010290\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010290.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010290.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010290.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010290.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010290.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717889579"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010290.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717889583"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010290.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc2ea5cc89377',t:'MTc0MDcxNzg5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 